Stockscreener 앱 받기
3.33
7.42%
0.23
시간 외 거래:
3.23
-0.10
-3.00%
전일 마감가:
$3.10
열려 있는:
$3.15
하루 거래량:
6.89M
Relative Volume:
2.22
시가총액:
$996.87M
수익:
-
순이익/손실:
$-241.99M
주가수익비율:
-3.5467
EPS:
-0.9389
순현금흐름:
$-133.64M
1주 성능:
+5.38%
1개월 성능:
-14.83%
6개월 성능:
+7.07%
1년 성능:
+2.46%
1일 변동 폭
$3.10
$3.3599
1주일 범위
$2.865
$3.3599
52주 변동 폭
$2.61
$6.55
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.33 | 937.00M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com Australia
Sana Biotechnology at wells fargo healthcare conference: two programs near clinic - Investing.com Canada
Sana Biotechnology | 8-K: Current report - Moomoo
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - The Conway Daily Sun
Sana Biotechnology to Present at September 2026 Investor Conferences - manilatimes.net
Four September presentations will feature Sana Biotechnology’s business update - Stock Titan
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer PATEL DHAVALKUMAR DHIRAJLALmoomoo - Moomoo
Sana (SANA) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison; Post-Report: Shares Finish 4.55% Higher in the Latest SessionRevenue Report - vinanet.vn
Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention - Kalkine Media
Is Sana Biotechnology (SANA) Turning Cost Discipline Into a More Durable Investment Narrative? - Sahm
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2%Time to Sell? - MarketBeat
Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely? - Moomoo
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9%Still a Buy? - MarketBeat
Can Sana Biotechnology (SANA) Justify Its Valuation On Narrower Losses? - Sahm
Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - The Globe and Mail
Morgan Stanley Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media
ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan
Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo
Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - MarketBeat
Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - MarketBeat
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0
Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SANA Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Capital DisciplineEarnings Surprise Report - vinanet.vn
SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Sana Biotechnology | 10-Q: Quarterly report - moomoo.com
Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade
Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India
Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com
Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget
Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - MarketBeat
Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net
Sana: Q2 Earnings Snapshot - KVUE
Sana Biotechnology | 8-K: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Moomoo
BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance
Sana Biotechnology (SANA) Advances 2.56% as Shares Approach Key Resistance at $3.79Dip Buy Trade - vinanet.vn
Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK
Sana Biotechnology faces earnings test as CAR-T program advances - Investing.com
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Harr Steve | President & CEO |
Mar 07 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
7,968,596 |
| Harr Steve | President & CEO |
Mar 06 '26 |
Option Exercise |
0.00 |
41,666 |
0 |
7,918,596 |
| Wyrick Susan D. | See Remarks |
Mar 07 '26 |
Option Exercise |
0.00 |
3,250 |
0 |
200,583 |
| Wyrick Susan D. | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
10,416 |
0 |
197,333 |
| Wyrick Susan D. | See Remarks |
Mar 02 '26 |
Option Exercise |
0.00 |
1,525 |
0 |
187,408 |
| Wyrick Susan D. | See Remarks |
Jan 02 '26 |
Option Exercise |
0.00 |
7,500 |
0 |
188,290 |
| Wyrick Susan D. | See Remarks |
Dec 13 '25 |
Option Exercise |
0.00 |
3,400 |
0 |
181,663 |
| Wyrick Susan D. | See Remarks |
Dec 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
180,828 |
0.14%
0.15%
자본화:
|
볼륨(24시간):